Jean-Luc M. Lemercier - 08 Apr 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEA, Canada, Latin Amer
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Apr 2022
Net transactions value
-$1,183,900
Form type
4
Filing time
11 Apr 2022, 19:03:18 UTC
Previous filing
11 Mar 2022
Next filing
05 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $253,722 +11,660 +7.7% $21.76 163,986 08 Apr 2022 Direct F1
transaction EW Common Stock Sale $12,357 -100 -0.06% $123.57 163,886 08 Apr 2022 Direct F1
transaction EW Common Stock Sale $1,425,265 -11,560 -7.1% $123.29 152,326 08 Apr 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -11,660 -50% $0.000000 11,560 08 Apr 2022 Common Stock 11,660 $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $122.57 to $123.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.